Moreover, anti-TNFα therapy reduced the numbers of CD3+ T-cells, CD22+ B-cells, and CD68+ macrophages in the joints of patients with RA over a 2 weeks period (Taylor et al., 2000). This evidence concerns the gene TNF and rheumatoid arthritis.